ORIGINAL RESEARCH article
Front. Immunol.
Sec. Molecular Innate Immunity
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1619448
MiRNA sequencing of platelet and exosome revealed platelet miR-199b-3p as a potential biomarker in lung adenocarcinoma
Provisionally accepted- 1Sichuan Cancer Hospital, Chengdu, China
- 2Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China
- 3Peking Union Medical Foundation, Beijing, Beijing Municipality, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Recent studies have shown that exosome microRNAs (miRNAs) can serve as effective biomarkers for cancer diagnosis, while platelet miRNAs are emerging as potential indicators as well. However, the distinctions between platelet and exosome miRNAs and the diagnostic value of platelet miRNAs in lung adenocarcinoma (LAC) remain poorly understood. This study aimed to elucidate these differences through miRNA sequencing of platelets and exosomes, exploring their association with LAC. We analyzed a cohort of 133 subjects, including 70 LAC patients, 31 healthy donors, and 32 patients with benign pulmonary nodules. Differentially expressed platelet miRNAs were identified, with platelet hsa-miR-199b-3p showing significantly lower expression in LAC patients compared to healthy individuals and those with benign nodules.Notably, ROC analysis indicated that hsa-miR-199b-3p exhibited robust diagnostic accuracy (AUC=0.73) for distinguishing LAC from benign nodules. This study highlights the potential of platelet hsa-miR-199b-3p as a non-invasive biomarker for differentiating benign and malignant pulmonary nodules, opening new avenues for innovative platelet miRNA-based liquid biopsy approaches in lung cancer diagnostics.
Keywords: Platelet, RNA sequencing, exosome, Lung Adenocarcinoma, Reference miRNA, liquid biopsy
Received: 24 Jun 2025; Accepted: 30 Jul 2025.
Copyright: © 2025 Wen, Yu, Leng, Liu and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Huaichao Luo, Sichuan Cancer Hospital, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.